首页 > 抗体蛋白 > 抗体
PerCP/Cyanine5.5 anti-mouse CD62L Antibody
产品名称:
PerCP/Cyanine5.5 anti-mouse CD62L Antibody
产品类别:
抗体
产品编号:
104431
产品应用:
104431
[价格]
规格 价格 库存
25µg ¥ 1416 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Lin D, et al. 2016. Cancer Res . 76: 3179 - 3188. PubMed
  2. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  3. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  4. Israelow B, et al. 2020. bioRxiv. . PubMed
  5. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  6. Cui N, et al. 2017. Chin Med J (Engl). 10.4103/0366-6999.205850. PubMed
  7. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  8. Wang D, et al. 2018. Immunity. 48:659. PubMed
  9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  10. Diao L, et al. 2022. iScience. 25:105511. PubMed
  11. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  12. Lu SX, et al. 2021. Cell. . PubMed
  13. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  14. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  15. van der Veeken J et al. 2019. Immunity. 50(5):1202-1217 . PubMed
  16. Ma C, et al. 2016. Nature. 531:253-257. PubMed
  17. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  18. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  19. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  20. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  21. Holz LE et al. 2018. Cell reports. 25(1):68-79 . PubMed
  22. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  23. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  24. Wang YT, et al. 2020. Nat Microbiol. 0.397222222. PubMed
  25. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  26. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  27. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  28. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  29. Baja?a S, et al. 2022. iScience. 25:103732. PubMed
  30. Basu J, et al. 2022. Commun Biol. 5:84. PubMed
  31. Dudeck J, et al. 2021. Immunity. 54(3):468-483.e5. PubMed
  32. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  33. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  34. Sheikh AA, et al. 2019. Cell Rep. 28:1758. PubMed
  35. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  36. Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed
  37. Nance J, et al. 2015. Proc Natl Acad Sci U S A. 112: 13324 - 13329. PubMed
  38. Xu X, et al. 2022. Cells. 11:. PubMed
  39. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_2187123 (BioLegend Cat. No. 104431) AB_2285839 (BioLegend Cat. No. 104432)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线